To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update
NEMA Research, Inc., Naples, FL, USA.
NEMA Research, Inc., Naples, FL, USA.
Department of Radiology, University of L'Aquila, L'Aquila, Italy.
Mid-Atlantic Pharm Tech, Ventnor, NJ, USA.
Show others and affiliations
2023 (English)In: Advances in Therapy, ISSN 0741-238X, E-ISSN 1865-8652, Vol. 40, p. 1334-1346Article, review/survey (Refereed) Published
Abstract [en]

The most common type of idiopathic interstitial pneumonia is idiopathic pulmonary fibrosis (IPF), an irreversible, progressive disorder that has lately come into question for possible associations with COVID-19. With few geographical exceptions, IPF is a rare disease but its prevalence has been increasing markedly since before the pandemic. Environmental exposures are frequently implicated in IPF although genetic factors play a role as well. In IPF, healthy lung tissue is progressively replaced with an abnormal extracellular matrix that impedes normal alveolar function while, at the same time, natural repair mechanisms become dysregulated. While chronic viral infections are known risk factors for IPF, acute infections are not and the link to COVID-19 has not been established. Macrophagy may be a frontline defense against any number of inflammatory pulmonary diseases, and the inflammatory cascade that may occur in patients with COVID-19 may disrupt the activity of monocytes and macrophages in clearing up fibrosis and remodeling lung tissue. It is unclear if COVID-19 infection is a risk factor for IPF, but the two can occur in the same patient with complicating effects. In light of its increasing prevalence, further study of IPF and its diagnosis and treatment is warranted.

Place, publisher, year, edition, pages
Springer, 2023. Vol. 40, p. 1334-1346
Keywords [en]
COVID-19, Idiopathic pulmonary fibrosis, Interstitial pneumonia, Macrophagy
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:oru:diva-103591DOI: 10.1007/s12325-022-02395-9ISI: 000919934600003PubMedID: 36692679Scopus ID: 2-s2.0-85146747868OAI: oai:DiVA.org:oru-103591DiVA, id: diva2:1731142
Available from: 2023-01-26 Created: 2023-01-26 Last updated: 2023-05-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Magnusson, Peter

Search in DiVA

By author/editor
Magnusson, Peter
By organisation
School of Medical Sciences
In the same journal
Advances in Therapy
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf